Equibles does not estimate personal net worth.
Get an email with a short summary when Opus Genetics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IRD alertsRob Gagnon is recorded as CFO at Opus Genetics, Inc. (IRD) since September 2, 2025. Opus Genetics, Inc. reported in an 8-K filed September 2, 2025 that Rob Gagnon was appointed Chief Financial Officer. Rob Gagnon has spoken on 1 investor event across 1 company, most recently for Opus Genetics, Inc. on October 20, 2026. Opus Genetics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Opus Genetics, Inc. includes Dr. George Magrath (CEO and Board Member), George Magrath (CEO and Board Member), George Magrath, M.D., M.B.A., M.S. (CEO and Board Member) and 7 others.
“Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, today announced the appointment of Rob Gagnon, CPA, MBA, as Chief Financial Officer.”
“So I'll start with the economics piece, and then, George, maybe you want to take the strategic piece on why this one's different. So we do earn a $10 million milestone associated with the approval.”
2025-09-02–present
Biotechnology · Healthcare
CFO
2025-09-02–present
